Tuttle Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Tuttle Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-492	Closed	-$380K	–	169
2026 Q1	$380K	Buy	+492	New	+$377K	0.63%	54
2020 Q4	–	Sell	-1,715	Closed	-$960K	–	243
2020 Q3	$960K	Buy	1,715 +1,027	+149%	+$623K	0.66%	27
2020 Q2	$429K	Buy	+688	New	+$391K	0.31%	76
2019 Q2	–	Sell	-2,491	Closed	-$1.02M	–	165
2019 Q1	$1.02M	Buy	+2,491	New	+$1.03M	0.21%	113

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Tuttle Capital Management's REGN Position: Q2 2026 in Review

Tuttle Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 492 shares — an estimated $380K sold.

Tuttle Capital Management first reported a position in REGN in Q1 2019 and held it in 4 quarters. The position peaked at $1.02M in Q1 2019. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Tuttle Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Tuttle Capital Management sold 492 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $380K.
Tuttle Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2019 and held it in 4 quarters.
Tuttle Capital Management's Regeneron Pharmaceuticals position peaked at $1.02M in Q1 2019.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Tuttle Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.